Cingulate Inc.
Cingulate Inc. (CING) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CING · as of Jun 8, 2026
Key Statistics
Explore Cingulate Inc. Data
cing stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 83.3%
The CING analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $10.00, representing +123.71% upside from the current price of $4.47.
Competitors & Peers
cing competitorsCING
ALLR
BCTX
CASI
CLSD
ENTOStock Performance
Full HistoryAbout Cingulate Inc.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its…
what is cingulate inc. · cing stock overview · cingulate inc. company profile · who is cingulate inc. ceo · cing NASDAQ · cingulate inc. headquarters · cingulate inc. business segments
About Stock Overview & Key Data
Cingulate Inc. (CING) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 8, 2021. As of the latest trading session, CING stock price is $4.47, with a market capitalization of $25.0M. The stock has returned -1.76% over the past 12 months and +2.76% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Cingulate Inc. stock is Buy, with an average 12-month price target of $10.00. In fiscal year 2025, Cingulate Inc. reported revenue of — and net income of -$22.4M. For detailed data — including Cingulate Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cingulate Inc. (CING) stock price is $4.47. The stock is traded on NASDAQ under the ticker symbol CING. The 52-week range is $3.16 – $11.89.